The Largest Overlooked Cost Driver in Viral Vector Production
Why nuclease strategy determines yield, quality, and cost per dose in your process
Based on experimental data and scenario cost model, the implementation of SAN HQ or M-SAN HQ has demonstrated:
2×
Increase in Yield
70%
Reduction in Nuclease Associated Cost
40%
Reduction in COGS per dose
Viral Vector Manufacturing Is Not Just About Yield - It's About Efficiency.
Today's AAV and lentiviral vector production are exposing hidden process costs, often limited by downstream bottlenecks. One critical parameter remains consistently underestimated:
The residual host cell DNA clearance efficiency and the nuclease strategy behind it.
The wrong nuclease strategy doesn't just affect purity.
It directly impacts cost:
Reduced chromatography efficiency
Increased enzyme consumption
Extended processing time
Lower recovery yields
Optimizing nuclease strategy is one of the fastest and lowest-risk levers to improve performance without process redesigning.
In our viral vector manufacturing processes, ArcticZymes’ M-SAN HQ and SAN HQ enzymes consistently deliver efficient host-cell DNA clearance under both physiological and high-salt conditions. This has allowed us to achieve reliable digestion with fewer nuclease units, improving process efficiency without compromising quality.
Team Lead, Viral Vector Process Development at Revvity